HS reports honoraria from Takeda, Ono, Fujimoto, Janssen, Chugai, Eisai, Sanofi, AstraZeneca, Meiji Seika Pharma, and AbbVie, research funding from Ono, Bristol Myers Squibb, and AbbVie. HH reports honoraria from Janssen, Bristol Myers Squibb, and Takeda, research funding from Bristol Myers Squibb and Takeda. AY reports honoraria from Kyowa Kirin, Chugai, Janssen, Sanofi, Bristol Myers Squibb, Eisai, Takeda, and Nippon-Shinyaku, research funding from Kyowa Kirin. SK reports honoraria from Eisai, Mundipharma, Chugai, Otsuka, Sanofi, Meiji Seika Pharma, AbbVie, Ono, Janssen, Takeda, Amgen, Novartis, and Nippon-Shinyaku. SO reports honoraria from Bristol Myers Squibb, Takeda, AstraZeneca, Janssen, and Sanofi. MY reports honoraria from Takeda, Sanofi, Novartis, Bristol Myers Squibb, Meiji Seika Pharma, and Daiichi Sankyo. SF reports honoraria from Takeda, Sanofi, Janssen, Ono, and Bristol Myers Squibb. TS reports honoraria from Ono, Otsuka, Eisai, SymBio, Takeda, Chugai, Sumitomo, Daiichi Sankyo, MSD, and PharmaEssentia. KM reports honoraria from Kyowa Kirin, Chugai, MSD, Teijin Pharma, Nippon-Shinyaku, Taiho, Takeda, Otsuka, Nippon Kayaku, Daiichi Sankyo, Sumitomo, Novartis, Pfizer, Celgene, Bristol Myers Squibb, Mochida, AbbVie, Alexion, Ono, Sanofi, Janssen, SymBio, AstraZeneca, CSL Bering, Amgen, Fujimoto, Eisai, Meiji Seika Pharma, Asahi Kasei, and Astellas, research funding from Kyowa Kirin, Chugai, MSD, Teijin Pharma, Nippon-Shinyaku, Taiho, Takeda, Otsuka, Nippon Kayaku, Daiichi Sankyo, and Sumitomo, advisory board fees from Bristol Myers Squibb, Novartis, and Otsuka, travel expense from Kyowa Kirin. HT reports honoraria from Sanofi, Ono, Janssen, Takeda, Bristol Myers Squibb, and Chugai, research funding from Asahi Kasei. MA reports honoraria from Takeda, Bristol Myers Squibb, Janssen, Sanofi, Ono, and Daiichi Sankyo. HI reports honoraria from Sanofi, SymBio, Janssen, Daiichi Sankyo, Chugai, Takeda, AstraZeneca, AbbVie, and Kyowa Kirin. JK reports honoraria from Janssen, Bristol Myers Squibb, Ono, Chugai, Takeda, Sanofi, and Kyowa Kirin, research funding from Kyowa Kirin, Mochida, Sanofi, Chugai, Bristol Myers Squibb, Takeda, and Ono, consulting fees from Janssen and Bristol Myers Squibb. HT reports honoraria from Janssen, Ono, Sanofi, and Bristol Myers Squibb, consulting fee from SRL, research funding from Bristol Myers Squibb. KS reports honoraria from Ono, Bristol Myers Squibb, Janssen, and Sanofi, research funding from Ono, Celgene, AbbVie, Takeda, Sanofi, Bristol Myers Squibb, GSK, Chugai, Otsuka, Janssen, MSD, Novartis, Pfizer, and Kyowa Kirin. MK reports honoraria from Bristol Myers Squibb, Novartis, Janssen, MSD, Nippon-Shinyaku, Ono, Takeda, and Sumitomo, research funding from Ono, Takeda, Kyowa Kirin, Chugai, and Daiichi Sankyo. TI reports honoraria from Takeda, Sanofi, Janssen, Bristol Myers Squibb, and Ono, research funding from Takeda, Pfizer, Sanofi, Janssen, and Bristol Myers Squibb. IM reports honoraria from Bristol Myers Squibb, Novartis, Otsuka, Pfizer, Janssen, Astellas, Takeda, Daiichi Sankyo, Ono, Chugai, AstraZeneca, SymBio, AbbVie, and Amgen, research funding from Ono, Janssen, Nippon-Shinyaku, Kyowa Kirin, Sumitomo, Shionogi, Teijin Pharma, Boehringer Ingelheim, Sanofi, Chugai, Eisai, MSD, Asahi Kasei, Astellas, Takeda, Nihon Pharma, Daiichi Sankyo, AbbVie, Taiho, Mitsubishi Tanabe, Nippon Kayaku, CSL Behring, Mundipharma, Ayumi Pharma, Eli Lilly Japan, Actelion Pharma, and Amgen, consulting fee from Otsuka. KA reports honoraria from AbbVie, Eisai, Ono, Kyowa Kirin, Chugai, Pfizer, Bristol Myers Squibb, and Janssen, research funding from Otsuka, Kyowa Kirin, Asahi Kasei, AbbVie, Chugai, and Takeda. SI reports honoraria from Janssen, Bristol Myers Squibb, Takeda, Sanofi, Ono, and Pfizer, research funding from Chugai, Janssen, Bristol Myers Squibb, Sanofi, Daiichi Sankyo, Pfizer, Celgene, Novartis, Ono, Takeda, Amgen, Shionogi, AbbVie, Otsuka, Kyowa Kirin, and GSK, advisory board fees from Janssen, Bristol Myers Squibb, Pfizer, Sanofi, AbbVie, Otsuka, Novartis, and Takeda. All the other authors have no conflicts of interest to disclose.